Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Endovascular management of acute ischemic stroke Gandhi CD; Christiano LD; Prestigiacomo CJNeurosurg Focus 2009[]; 26 (3): E2The management of stroke has progressed significantly over the past 2 decades due to successful treatment protocols including intravenous and intraarterial options. The intravenous administration of tissue plasminogen activator within an established treatment window has been proven in large, well-designed studies. The evolution of endovascular strategies for acute stroke has been prompted by the limits of the intravenous treatment, as well as by the desire to demonstrate improved recanalization rates and improved long-term outcomes. The interventional treatment options available today are the intraarterial administration of tissue plasminogen activator and newer antiplatelet agents, mechanical thrombectomy with the MERCI device and the Penumbra system, and intracranial angioplasty and stent placement. In this review the authors outline the major studies that have defined the current field of acute stroke management and discuss the basic treatment paradigms that are commonly used today.|Abciximab[MESH]|Angioplasty, Balloon[MESH]|Angioplasty/instrumentation/methods[MESH]|Antibodies, Monoclonal/therapeutic use[MESH]|Humans[MESH]|Immunoglobulin Fab Fragments/therapeutic use[MESH]|Infusions, Intravenous[MESH]|Platelet Aggregation Inhibitors/therapeutic use[MESH]|Stents[MESH]|Stroke/*diagnosis/*therapy[MESH]|Thrombectomy/*methods[MESH]|Thrombolytic Therapy/instrumentation/*methods[MESH]|Time Factors[MESH]|Tissue Plasminogen Activator/administration & dosage[MESH] |
